Product Description
BNT212 is a CAR-T cell therapy directed against the tumor antigen Claudin 18.2 (CLDN18.2), which is expressed in numerous epithelial solid tumors, including gastric, pancreatic, esophageal, ovarian and lung tumors. (Sourced from: https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt212-pancreatic-cancer)
Mechanisms of Action: CAR-T,CLDN18.2
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioNTech
Company Location: MAINZ 2M 55131
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|